Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Tyco Makes Space For General Surgical Innovations Alongside USSC

This article was originally published in The Gray Sheet

Executive Summary

Tyco International's $100 mil. stock-swap acquisition of minimally invasive balloon dissection device maker General Surgical Innovations is expected to close within the next 90 days, GSI estimates.

You may also be interested in...



Tyco Takes Steps To Add InnerDyne Surgical Access Line Via $180 Mil. Bid

Tyco International's purchase of InnerDyne for $180 mil. would give the company access to the Sunnyvale, Calif. firm's Step line of minimally invasive access products for laparoscopic surgery.

Tyco Takes Steps To Add InnerDyne Surgical Access Line Via $180 Mil. Bid

Tyco International's purchase of InnerDyne for $180 mil. would give the company access to the Sunnyvale, Calif. firm's Step line of minimally invasive access products for laparoscopic surgery.

General Surgical Innovations/Dexterity Surgical, Inc.

GSI's Spacemaker balloon dissector products will be offered by Dexterity Surgical's 100-rep sales force under a distribution contract announced May 26. GSI hopes to capture share in the hernia and stress urinary incontinence repair markets, capitalizing on its successful court injunction of sales of Guidant's PDB1000, PDB2, ExtraView and VasoView devices, manufactured by its Origin Medsystems subsidiary ("The Gray Sheet" April 19, p. 22). Dexterity previously distributed the Origin products

Related Content

Latest Headlines
See All
UsernamePublicRestriction

Register

MT012248

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel